Quick Answer
vTv Therapeutics Inc. reported Total Assets of $89.90 million for the year ending 2025.
- vTv Therapeutics Inc. showed an increase of +134.9% in Total Assets from 2024 to 2025.
- This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $100.20 million | Q1 2016: $79.56 million | Q2 2016: $66.78 million | Q3 2016: $54.72 million | Q1 2017: $48.33 million | Q2 2017: $35.78 million | Q3 2017: $24.06 million | Q1 2018: $14.73 million | Q2 2018: $11.23 million | Q3 2018: $11.09 million | Q1 2019: $10.74 million | Q2 2019: $9.07 million | Q3 2019: $9.12 million | Q1 2020: $7.39 million | Q2 2020: $10.63 million | Q3 2020: $7.05 million | Q1 2021: $16.75 million | Q2 2021: $21.66 million | Q3 2021: $31.43 million | Q1 2022: $20.19 million | Q2 2022: $36.99 million | Q3 2022: $35.52 million | Q1 2023: $28.83 million | Q2 2023: $22.43 million | Q3 2023: $14.92 million | Q1 2024: $54.18 million | Q2 2024: $46.46 million | Q3 2024: $43.16 million | Q1 2025: $32.03 million | Q2 2025: $26.45 million | Q3 2025: $99.49 million.
- Over the full 12 years of available data (2014 to 2025), vTv Therapeutics Inc.'s Total Assets has grown by 594.1%.
- Historical annual values: Fiscal year 2025: $89.90 million | Fiscal year 2024: $38.27 million | Fiscal year 2023: $11.02 million | Fiscal year 2022: $33.24 million | Fiscal year 2021: $25.47 million | Fiscal year 2020: $14.79 million | Fiscal year 2019: $9.27 million | Fiscal year 2018: $8.56 million | Fiscal year 2017: $27.92 million | Fiscal year 2016: $54.50 million | Fiscal year 2015: $91.53 million | Fiscal year 2014: $12.95 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: